AI assistant
Celyad Oncology SA — Director's Dealing 2014
Jun 25, 2014
3927_mrq_2014-06-25_ccdbc646-30c0-450f-898d-226387d29fa2.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Transparency Notification Mayo Foundation for Medical Education and Research
(Article 14 of the Law of 2 August 2007)
Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, today announces it has received a transparency declaration from Mayo Foundation for Medical Education and Research in accordance with the Belgian Law of 2nd May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market.
As of today, the Company's share capital amounts to EUR 23,582,640.63 and is represented by a total 6,745,547 shares (each share given one voting right).
Transparency notification from Mayo Foundation for Medical Education and Research
Cardio3 BioSciences, received on 25 June 2014, a transparency notification from Mayo Medical Education and Research, having passed, on 20 June 2014, the 5% threshold.
-
Reason for notification: transfer of shares to Mayo's Foundation employees and technology inventors
-
Notification by a person that notifies alone.
- Person holdings notification
| Name | Address |
|---|---|
| Mayo Foundation for Medical Education and Research |
200 First Street, Rochester, MN 55906-001, USA |
| Voting rights | Previous notification |
Post the transaction | ||||
|---|---|---|---|---|---|---|
| # voting rights | # voting rights | % voting rights | ||||
| Holders of voting rights |
Attached to shares |
Non related securities |
Attached to shares |
Non related securities |
||
| MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
340,947 | 211,135 | - | 3.13% | - | |
| TOTAL | 211,135 | - | 3.13% | - |
Regulated information Press release 25 June 2014 – 17:45 CET
For more information contact:
Cardio3 BioSciences Dr Christian Homsy, CEO Anne Portzenheim, Communication Manager
Citigate Dewe Rogerson David Dible/Chris Gardner/Malcolm Robertson www.c3bs.com Tel : +32 10 39 41 00 [email protected]
Tel : +44 (0) 207 638 9571 [email protected]
About Cardio3 BioSciences
Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the USA and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.
The Company's lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to regenerate the heart. This process is known as Cardiopoiesis.
Cardio3 BioSciences has also developed C-Cath®ez, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.
Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.
C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forwardlooking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.